Drug Profile
Tagatose - Dominari Holdings
Alternative Names: D-tagatose; NaturloseLatest Information Update: 31 Mar 2023
Price :
$50
*
At a glance
- Originator Spherix
- Developer Dominari Holdings; Spherix
- Class Hexoses; Obesity therapies; Small molecules
- Mechanism of Action Iron chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Type 2 diabetes mellitus
Highest Development Phases
- Suspended Type 2 diabetes mellitus
- Discontinued Hypertriglyceridaemia
Most Recent Events
- 06 Mar 2020 Spherix is now called AIkido Pharma
- 29 Mar 2012 Discontinued - Preclinical for Hypertriglyceridaemia in USA (unspecified route)
- 21 Jan 2011 Spherix completes a phase II trial in Type-2 diabetes mellitus in USA and India (NCT00961662)